PMC-402 / PharmAbcine - LARVOL DELTA

[VIRTUAL] PharmAbcine (BIO 2020) - "Olinvacimab is in several clinical trials globally as single but also combination with Keytruda with MERCK. PMC-309, anti-VISTA neutralizing antibody and PMC-402, anti-TIE2 agonizing antibody are in oncology program and will be in Phase I in 2021."

Oncology

PharmAbcine to participate in BIO Digital Conference (BioSpace) - "'By participating in BIO Digital, the company aims to introduce its front runner product, olinvacimab, an angiogenesis regulator, and the two new additions to its pipeline,' says Dr. Jin-San Yoo, CEO of PharmAbcine. 'The two new additions include 1) PMC-402, a TIE-2 activating blood vessel stabilizer and 2) PMC-309, an anti-VISTA immune checkpoint inhibitor.'"

Clinical • Oncology

PharmAbcine to present preclinical data of blood vessel stabilizing PMC-402 at 2020 AACR Meeting (BioSpace) - "PharmAbcine Inc…announced today that it will present preclinical data of PMC-402, an active vessel stabilizing monoclonal antibody, at the 2020 American Association for Cancer Research (AACR). The meeting will be held on June. 22nd – June. 24th. All poster presentations will be made available online on the first day of the meeting…The highlight of the presentation will be the anti-tumor effects observed in a mouse model for colon cancer following the treatment of a single agent or combination with anti-PD1 antibody."

Preclinical • Oncology